🔍

ASTERDM - Aster DM Health.

📊 NSE: ASTERDM 🏢 Healthcare 📅 Last Updated: 12/13/2025 18:39

📢 Recent Corporate Announcements

Aster DM Healthcare Releases Q4 and FY26 Earnings Call Recording

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 01 May 2026, 09:47 PM

Aster DM Healthcare has officially released the video and audio recordings of its earnings call for the quarter and financial year ended March 31, 2026. The call, which took place on May 01, 2026, provided management's perspective on the company's annual performance and future strategy. This disclosure is a standard regulatory requirement under SEBI Listing Regulations to ensure transparency for all shareholders. Investors can access the full recording via the company's investor relations portal.

Earnings call for the quarter and year ended March 31, 2026, concluded on May 01, 2026.
Video and audio recordings are now accessible on the company's official website.
Compliance filing submitted under Regulation 30 of SEBI Listing Regulations.
The recording provides detailed management commentary on the FY26 financial results.

💡 Investors should listen to the recording to understand management's outlook on hospital occupancy rates and expansion plans for the next fiscal year.

Aster DM Q4FY26 Combined Revenue Up 18% to ₹2,361 Cr; Merger with QCIL Nears Completion

🟢 POSITIVE ⭐ 9/10

EARNINGS 📅 30 Apr 2026, 07:42 PM

Aster DM Healthcare reported strong proforma combined results for Q4FY26, with revenue growing 18% YoY to ₹2,361 crore and EBITDA rising 25% to ₹517 crore. The company's operational efficiency improved significantly, with EBITDA margins expanding to 21.9% and RoCE reaching 21.1%. The merger with Quality Care (QCIL) is on track for completion in Q1 FY27, having received 96.68% shareholder approval. Looking ahead, the company plans to expand its bed capacity by 4,445 beds to reach a total of 15,068 beds by FY30.

Combined proforma revenue for Q4FY26 grew 18% YoY to ₹2,361 crore, while FY26 revenue reached ₹9,273 crore.
Operating EBITDA for the combined entity increased 25% YoY to ₹517 crore in Q4, with margins improving by 118 bps to 21.9%.
Total patient volumes rose 12% YoY to 1.93 million, supported by a 210 bps increase in occupancy to 61%.
The merger with Quality Care (QCIL) is expected to conclude in Q1 FY27, creating a massive healthcare platform with a pipeline to reach 15,068 beds.
Standalone India business (Aster) saw a 32% YoY growth in normalized PAT to ₹140 crore for the quarter.

💡 Investors should view the strong margin expansion and the imminent merger with QCIL as significant value drivers. The aggressive bed expansion plan provides a clear long-term growth trajectory for the combined entity.

Aster DM Q4 FY26: Revenue up 18% to ₹1,182 Cr; EBITDA (ex-Kasargod) jumps 31%

🟢 POSITIVE ⭐ 9/10

EARNINGS 📅 30 Apr 2026, 04:10 PM

Aster DM Healthcare reported a robust Q4 FY26 with revenue growing 18% YoY to INR 1,182 Cr and normalized PAT (ex-Kasargod) surging 45% to INR 153 Cr. Operating EBITDA margins (ex-Kasargod) improved significantly to 21.7% from 19.3% in the previous year, driven by operating leverage and disciplined cost management. The merger with Quality Care India Ltd (QCIL) is on track for completion in Q1 FY27, having received 96.68% shareholder approval. On a proforma basis, the combined entity's revenue reached INR 2,361 Cr with a healthy EBITDA margin of 21.9%.

Revenue for Q4 FY26 grew 18% YoY to INR 1,182 Cr; Operating EBITDA (ex-Kasaragod) rose 31% to INR 253 Cr.
Normalised PAT (ex-Kasaragod) witnessed a robust 45% YoY growth, reaching INR 153 Cr.
Average Revenue Per Occupied Bed (ARPP) for IP rose 9% YoY to INR 1,25,234, with total patient volumes up 15%.
Medical Value Travel (MVT) revenue grew by 41% YoY, led by a 51% surge in Kerala MVT revenue.
Merger with QCIL is expected to close in Q1 FY27, creating a platform with over 10,623 beds across 28 cities.

💡 Investors should note the strong margin expansion and the significant growth in Medical Value Travel as positive indicators of operational efficiency. The upcoming merger with QCIL is a major catalyst that will scale the company into one of India's top three healthcare providers.

Aster DM Healthcare Board Approves FY26 Audited Results; Auditors Issue Unmodified Opinion

🟡 NEUTRAL ⭐ 7/10

EARNINGS 📅 30 Apr 2026, 04:03 PM

Aster DM Healthcare's Board of Directors approved the audited standalone and consolidated financial results for the quarter and full year ended March 31, 2026. Statutory auditors Deloitte Haskins & Sells issued an unmodified opinion, confirming the financial statements present a true and fair view of the company's performance. The results incorporate the DM Healthcare Employees Welfare Trust, which reported total assets of INR 19.57 crores. This announcement confirms the completion of the annual audit process without any reported accounting discrepancies.

Board approved audited standalone and consolidated financial results for the fiscal year ended March 31, 2026.
Statutory auditors Deloitte Haskins & Sells issued an unmodified audit opinion for the full financial year.
The DM Healthcare Employees Welfare Trust (ESOP Trust) reported total assets of INR 19.57 crores before eliminations.
The board meeting was conducted over a five-hour session, concluding at 3:35 PM IST on April 30, 2026.

💡 Investors should review the detailed profit and loss statements and balance sheet once the full tables are released to assess operational margins. The unmodified audit opinion is a positive indicator of the company's financial reporting integrity.

Aster DM Healthcare to Host Q4 & FY26 Earnings Call on May 1, 2026

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 27 Apr 2026, 06:04 PM

Aster DM Healthcare Limited has scheduled its earnings conference call for Friday, May 1, 2026, at 11:00 AM IST. The call will focus on the audited financial results for the fourth quarter and the full fiscal year ended March 31, 2026. Senior leadership, including Founder Chairman Dr. Azad Moopen and Deputy MD Ms. Alisha Moopen, will be present to discuss performance and outlook. This is a standard regulatory filing following the conclusion of the fiscal year.

Earnings conference call scheduled for May 1, 2026, at 11:00 AM IST.
Discussion will cover audited financial results for Q4 and Full Year FY26.
Top management including Chairman, Deputy MD, COO, and CFO to participate.
Registration link provided for institutional investors and analysts to join the session.

💡 Investors should attend or review the transcript of the call to understand the company's growth trajectory and margin guidance for the upcoming fiscal year. No immediate trading action is required based on this scheduling announcement.

Aster DM Completes 26% Stake Acquisition in Oyster Green Hybrid for Revised INR 5.80 Cr

🟢 POSITIVE ⭐ 6/10

M&A 📅 23 Apr 2026, 04:07 PM

Aster DM Healthcare and its subsidiary MIMS have finalized the acquisition of a 26% stake in Oyster Green Hybrid Two Private Limited. The total consideration was revised downward to INR 5.80 crore from the initial INR 7 crore due to a reduction in overall project costs. This acquisition is a strategic move to fulfill statutory requirements for a captive 18 MWp solar power plant in Kerala, which will supply 100% of its net output to the group's facilities. The final tranche of INR 2.26 crore was completed on April 22, 2026, marking the formal conclusion of the deal.

Acquisition of 26% equity stake in Oyster Green Hybrid Two Private Limited completed.
Total investment revised to INR 5.80 crore from the earlier estimate of INR 7 crore.
The deal enables access to an 18 MWp captive solar power plant project in Kerala.
Final payment tranche of INR 2.26 crore executed on April 22, 2026.
Move aimed at meeting electricity requirements through renewable energy sources and reducing long-term costs.

💡 This is a positive step towards operational efficiency and ESG compliance through renewable energy adoption. While the transaction size is small, it reflects disciplined capital allocation by reducing the acquisition cost in line with project expenses.

Aster DM Shareholders Approve Dr. Azad Moopen's Appointment; Section 185 Resolution Narrowly Passes

🔵 WATCH ⭐ 7/10

MANAGEMENT 📅 15 Apr 2026, 07:11 PM

Aster DM Healthcare's shareholders have approved the appointment of Dr. Mandayapurath Azad Moopen as Executive Director with 99.84% support. A second special resolution regarding the granting of loans and guarantees under Section 185 also passed, but with a much narrower margin of 75.57%. Notably, institutional investors showed strong resistance to the loan resolution, with 64.22% of their votes cast against it. This suggests a significant divide between the promoter group and institutional shareholders regarding corporate lending and guarantee practices.

Dr. Azad Moopen's appointment as Executive Director received 47.40 crore votes in favour (99.84%).
Section 185 resolution for loans and guarantees passed with 75.57% favour, just clearing the 75% special resolution hurdle.
Institutional investors cast 11.60 crore votes (64.22% of their category) against the Section 185 resolution.
Promoter group voted 100% in favour of both resolutions, representing 21.76 crore shares.
Total of 47.48 crore valid votes were polled for the loan resolution out of 1.39 lakh eligible shareholders.

💡 While leadership remains stable, investors should exercise caution and monitor the company's future inter-corporate loan activities given the high level of institutional dissent. The narrow passing of the Section 185 resolution indicates that institutional shareholders may have concerns regarding capital allocation.

Aster DM Expands Whitefield Hospital Capacity to 539 Beds with Rs 96 Cr Investment

🟢 POSITIVE ⭐ 7/10

EXPANSION 📅 13 Apr 2026, 10:37 AM

Aster DM Healthcare has invested Rs 96 crore to expand its specialized 'Women & Children' facility at Aster Whitefield Hospital in Bengaluru. This expansion adds 159 beds, increasing the total capacity of the Whitefield unit from 380 to 539 beds. The move is part of a larger regional strategy to reach 2,573 beds in Karnataka, including upcoming projects in Yeshwantpur and Sarjapur. The facility focuses on high-margin specialized services such as Level 3A NICU, fetal medicine, and fertility treatments.

Investment of Rs 96 crore to add a dedicated 159-bed specialized facility
Aster Whitefield's total bed capacity increased from 380 to 539 beds
Total Karnataka bed capacity to reach 2,573 beds with upcoming Yeshwantpur and Sarjapur facilities
Facility features advanced services including Level 3A NICU, water birthing, and fetal surgery
Aster DM currently operates 20 hospitals with 5,451 beds across India

💡 Investors should monitor the ramp-up in occupancy for the new beds as it will drive revenue growth in the high-margin mother and child segment. The expansion reinforces Aster's focus on the Indian market following its recent GCC business divestment.

Aster DM Healthcare Announces Rs 3 Interim Dividend; Sets April 3, 2026 as Record Date

🟢 POSITIVE ⭐ 7/10

DIVIDEND 📅 27 Mar 2026, 06:43 PM

Aster DM Healthcare has declared an interim dividend of Rs 3 per equity share for the financial year 2025-26. The company has fixed April 3, 2026, as the record date to determine shareholder eligibility for the payout. Tax will be deducted at source (TDS) at a rate of 10% for resident shareholders with a valid PAN for dividends exceeding Rs 10,000. Shareholders must submit relevant tax exemption documents or DTAA declarations by the deadline of April 6, 2026.

Interim dividend declared at Rs 3 per equity share for the financial year 2025-26.
Record date for dividend entitlement is fixed as April 3, 2026.
Standard TDS rate of 10% applies to resident shareholders with valid PAN for dividends above Rs 10,000.
A higher TDS rate of 20% will be applied if PAN is invalid or not linked with Aadhaar.
Deadline for submitting tax-related documents and declarations is April 6, 2026.

💡 Investors should ensure their PAN is linked with Aadhaar and bank account details are updated with their Depository Participant to receive the dividend. Eligible shareholders should submit tax exemption forms like Form 121 or DTAA documents before April 6 to avoid higher tax withholding.

Aster DM Healthcare Declares Rs 3 Interim Dividend; Record Date April 3, 2026

🟢 POSITIVE ⭐ 7/10

DIVIDEND 📅 26 Mar 2026, 02:23 PM

Aster DM Healthcare has declared an interim dividend of Rs 3 per equity share for the financial year 2025-26, representing 30% of the face value of Rs 10. The Board has fixed April 3, 2026, as the record date to determine eligible shareholders. The dividend payment will be processed within 30 days from the declaration date of March 26, 2026. Shareholders are required to submit tax-related documents by April 6, 2026, to ensure appropriate TDS rates are applied.

Interim dividend of Rs 3 per equity share for FY 2025-26
Record date for dividend entitlement set for April 3, 2026
Dividend payment to be completed within 30 days of declaration
Deadline for submitting TDS-related documents is April 6, 2026

💡 Investors interested in the dividend should ensure they hold the stock before the ex-dividend date. Existing shareholders should submit necessary tax documents by April 6 to avoid higher TDS.

Aster DM Healthcare Declares Interim Dividend of Rs. 3 Per Share for FY 2025-26

🟢 POSITIVE ⭐ 7/10

DIVIDEND 📅 26 Mar 2026, 02:22 PM

Aster DM Healthcare's Board of Directors has declared an interim dividend of Rs. 3 per equity share for the financial year 2025-26. The dividend is based on a face value of Rs. 10 per share. The company has established April 3, 2026, as the record date to identify eligible shareholders for this payout. The dividend will be paid within 30 days of declaration, after accounting for applicable Tax Deducted at Source (TDS).

Interim dividend of Rs. 3 per equity share declared for the financial year 2025-26.
Record date for determining shareholder eligibility is fixed as April 3, 2026.
Dividend payment will be processed within 30 days from the date of declaration.
The dividend is subject to TDS as per the provisions of the Income Tax Act, 1961.

💡 Investors interested in the dividend should ensure they own the stock before the record date of April 3, 2026. This payout reflects the company's commitment to returning value to shareholders.

Aster DM Healthcare Receives GST Demand and Penalty of Rs 72.9 Lakh

🟡 NEUTRAL ⭐ 3/10

REGULATORY 📅 25 Mar 2026, 06:04 PM

Aster DM Healthcare has received a tax order from the Assistant Commissioner, Kochi Commissionerate, for the period FY 2019-20 to 2023-24. The order alleges non-payment of GST on insurance processing fees, resulting in a total demand of Rs 72,90,932. This demand consists of Rs 36,45,466 in tax and an equal penalty of Rs 36,45,466. The company has stated that this order has no material impact on its financials and it intends to file an appeal against the decision.

Total tax demand and penalty amounting to Rs 72,90,932 received under Section 74 of the CGST Act
Demand includes a tax component of Rs 36,45,466 and a penalty of Rs 36,45,466
The dispute pertains to GST on insurance processing fees for the five-year period from FY 2019-20 to 2023-24
Management confirms no material impact on operations or financials and will pursue legal remedies

💡 This is a minor regulatory matter with negligible financial impact relative to the company's scale. No immediate action is required as the company plans to appeal the order.

Aster DM Healthcare to Meet Institutional Investors in Bengaluru on March 27, 2026

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 23 Mar 2026, 06:16 PM

Aster DM Healthcare Limited has announced a group meeting with institutional investors and analysts scheduled for March 27, 2026. The meeting is organized by ICICI Securities Limited and will be held in-person in Bengaluru, Karnataka. This disclosure is a routine compliance filing under Regulation 30 of SEBI (LODR) Regulations, 2015. The company has explicitly stated that no unpublished price sensitive information (UPSI) will be shared during this interaction.

Group meeting with analysts and institutional investors scheduled for March 27, 2026.
The event is organized by ICICI Securities Limited and will be conducted in-person.
Location of the meeting is confirmed as Bengaluru, Karnataka.
Company confirms that no unpublished price sensitive information (UPSI) will be disclosed.
Filing made in compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

💡 Investors should monitor for any post-meeting presentations or transcripts that may be uploaded to the stock exchanges for insights into management's outlook. No immediate action is required as this is a routine administrative disclosure.

Aster DM Healthcare Closes Trading Window from March 19, 2026, Ahead of FY26 Results

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 19 Mar 2026, 10:09 AM

Aster DM Healthcare has announced the closure of its trading window for all designated persons and their immediate relatives starting March 19, 2026. This action is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, ahead of the financial results for the quarter and year ending March 31, 2026. The window will remain closed until 48 hours after the official declaration of these standalone and consolidated financial results. This is a standard regulatory procedure to prevent insider trading during the period when sensitive financial information is being finalized.

Trading window for designated persons closed effective March 19, 2026
Closure pertains to the financial results for the quarter and year ending March 31, 2026
Window to reopen 48 hours after the declaration of standalone and consolidated results
Compliance maintained as per SEBI circular SEBI/HO/ISD/ISD-POD-2/P/CIR/2025/55

💡 No action is required as this is a routine regulatory filing; investors should monitor the company's upcoming earnings release for fundamental performance updates.

Aster DM Reports ₹17.69 Cr Revenue Loss Due to Kerala Nurse Strike; High Court Intervenes

🔴 NEGATIVE ⭐ 7/10

OTHER 📅 14 Mar 2026, 02:24 PM

Aster DM Healthcare has reported a revenue loss of ₹17.69 crore between March 8 and March 13, 2026, due to a statewide nurse strike in Kerala affecting seven of its hospitals. The Kerala High Court has intervened, directing the United Nurses Association to defer the strike until March 19 and move to mediation for wage negotiations. The company anticipates a further potential loss of ₹5.33 crore if the situation resolves by the court-mandated deadline. Management has activated contingency plans, including mobilizing staff from Karnataka, to maintain critical services.

Reported revenue loss of ₹17.69 crore from March 8 to March 13, 2026
Estimated additional loss of up to ₹5.33 crore expected until March 19
Kerala High Court ordered a temporary halt to the strike and referred the dispute to mediation
Strike affected seven major hospitals including Aster Medcity and MIMS units in Kerala
Company mobilized nursing staff from neighboring Karnataka to ensure continuity of critical care

💡 Investors should monitor the mediation outcome on March 19, as a permanent wage hike could impact long-term margins in the Kerala cluster. The current financial impact is manageable but highlights labor risks in a core operating region.

View All ASTERDM Announcements on Live Market Tracking →

💰 Financial Performance

Revenue Growth by Segment

The core Hospitals and Clinics segment, which contributes 94% of total revenue, grew 10% YoY in Q2 FY26 to INR 1,160 Cr. Aster Labs revenue grew 15% YoY in Q2 FY26, while the Pharmacy business saw a revenue decrease to INR 134 Cr in FY25 from INR 168 Cr in FY24 due to a strategic exit from loss-making wholesale units.

Geographic Revenue Split

Operations are heavily concentrated in South India, with key clusters in Kerala, Karnataka, Andhra Pradesh, and Telangana. Kerala remains a primary market, showing steady recovery and contributing significantly to the 20% revenue CAGR over the last five years.

Profitability Margins

Operating Profit Margin (OPM) improved to 18.7% in FY25 from 15.9% in FY24. In Q2 FY26, the margin reached 22.0%, up from 21.4% in Q2 FY25. Normalised PAT (Post-NCI) for Q2 FY26 was INR 110 Cr, a 14% increase YoY from INR 97 Cr.

EBITDA Margin

Operating EBITDA margin stood at 22.0% in Q2 FY26, a 53 bps improvement YoY. Core hospital business delivered a higher margin of 24.4%, while matured hospitals achieved 26.5% in Q2 FY26. EBITDA grew 13% YoY to INR 263 Cr in Q2 FY26.

Capital Expenditure

Planned capital expenditure of approximately INR 2,500 Cr to add 2,600 beds by FY2029, with INR 400 Cr already incurred as of June 30, 2025. An additional INR 900-1,000 Cr is allocated for incremental bed capacity and maintenance between FY24 and FY26.

Credit Rating & Borrowing

ICRA upgraded ratings on bank lines totaling INR 602 Cr. Total debt as of March 31, 2025, was INR 2,017.8 Cr (including INR 1,375.6 Cr in lease liabilities). Net Debt/EBITDA improved significantly to 0.8x following the GCC business sale proceeds.

⚙️ Operational Drivers

Raw Materials

Primary costs include medical consumables, pharmaceuticals (representing the bulk of the 6% revenue from labs/pharmacy), and medical equipment. Specific percentage of total cost per item is not disclosed.

Import Sources

Not specifically disclosed in available documents, though medical equipment is noted as a key investment area for capacity expansion.

Capacity Expansion

Current capacity is 5,159 beds (FY25). The company plans to add 2,300+ beds to reach a total capacity of 7,800+ beds, with 234 beds in FY26, 1,054 in FY27, and 1,080 beyond FY27.

Raw Material Costs

Not disclosed as a specific percentage of revenue, but procurement synergies and group-strength negotiations are used to manage costs. Pharmacy business strategic exits were made to improve overall profitability.

Manufacturing Efficiency

Occupancy stood at 62% in FY25. Average Revenue Per Occupied Bed (ARPOB) increased 12% YoY to INR 45,000 in FY25. Average Length of Stay (ALOS) improved to 3.2 days from 3.4 days.

📈 Strategic Growth

Expected Growth Rate

20%

Growth Strategy

Growth will be driven by adding 2,300+ beds by FY27, optimizing the payor mix (currently 81% cash and insurance), and expanding the O&M asset-light model in emerging regional cities. The company is also integrating with Quality Care India Limited (QCIL) to create a merged entity with 7,800+ capacity beds.

Products & Services

Quaternary and tertiary healthcare services, oncology treatments (grew 26% YoY), diagnostic lab tests, and retail/wholesale pharmacy products.

Brand Portfolio

Aster DM Healthcare, Aster Medcity, Aster MIMS, Aster Whitefield, Aster Aadhar, Aster Labs, and Aster Health App.

New Products/Services

The Aster Health App, launched in November 2024, has achieved over 100,000 downloads to enhance digital patient engagement.

Market Expansion

Expansion into Northern Kerala (Kasargod) and deeper penetration into Karnataka, Maharashtra, Andhra Pradesh, and Telangana clusters.

Strategic Alliances

Merger with Quality Care India Limited (QCIL) to scale operations to a proforma revenue of INR 2,390 Cr for the merged entity.

🌍 External Factors

Industry Trends

The industry is shifting toward high-acuity and complex care in urban centers. Aster has positioned itself with a 20% revenue CAGR and 38% EBITDA CAGR over 5 years, outperforming general market growth through quaternary care focus.

Competitive Landscape

Faces competition from regional hospital chains in South India and national players; competitive pressure is a noted risk for geographic concentration.

Competitive Moat

Moat is built on a strong brand presence in South India, high-end quaternary care capabilities (e.g., Aster Medcity), and an established referral network from the GCC region. These are sustainable due to high switching costs in complex healthcare and long-term doctor-patient relationships.

Macro Economic Sensitivity

Sensitive to medical tourism trends, particularly from GCC countries to Indian hospitals, which helps mitigate regional economic risks.

Consumer Behavior

Increasing demand for digital healthcare convenience, addressed by the launch of the Aster Health App.

Geopolitical Risks

The segregation of the GCC business reduces direct exposure to Middle Eastern geopolitical shifts, though the brand remains leveraged in that region for medical tourism.

⚖️ Regulatory & Governance

Industry Regulations

Subject to price-control measures and high compliance standards for healthcare services. Recent CGHS price increases for 2,000+ procedures provided a positive revenue impact of INR 2 Cr per month.

Taxation Policy Impact

FY24 results excluded a one-time impact of INR 52.4 Cr due to the recognition of Net Deferred Tax Liability.

Legal Contingencies

The company faces moderate social risks including litigation exposure and high compliance requirements typical of the healthcare sector. Specific case values are not disclosed.

⚠️ Risk Analysis

Key Uncertainties

Regulatory price caps and changes in government healthcare schemes (CGHS/ESI) could impact margins by 35-40 basis points of EBITDA.

Geographic Concentration Risk

High dependence on South India; regional economic downturns or regulatory changes in Kerala or Karnataka could significantly impact the 94% revenue share from hospitals.